BR103354

Overview

BR103354 is an orally active, selective fibroblast activation protein ( FAP ) inhibitor with an IC 50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP , decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Type 2 Diabetes | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > FAP | Products > Signaling Pathways > ERK | Products > Signaling Pathways > GLUT

Product Information

• Catalog No.: HY-182250
• CAS No.: 2505339-87-5
• Molecular Formula: C19H15F2N5O2S
• Molecular Weight: 415.42
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source